From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer
- PMID: 31918176
- DOI: 10.1016/j.nutres.2019.12.004
From tea to treatment; epigallocatechin gallate and its potential involvement in minimizing the metabolic changes in cancer
Abstract
As the most abundant bioactive polyphenol in green tea, epigallocatechin gallate (EGCG) is a promising natural product that should be used in the discovery and development of potential drug leads. Due to its association with chemoprevention, EGCG may find a role in the development of therapeutics for prostate cancer. Natural products have long been used as a scaffold for drug design, as their already noted bioactivity can help accelerate the development of novel treatments. Green tea and the EGCG contained within have become associated with chemoprevention, and both in vitro and in vivo studies have correlated EGCG to inhibiting cell growth and increasing the metabolic stress of cancer cells, possibly giving merit to its long utilized therapeutic use in traditional therapies. There is accumulating evidence to suggest EGCG's role as an inhibitor of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling cascade, acting upon major axis points within cancer survival pathways. The purpose of this review is to examine the research conducted on tea along with EGCG in the areas of the treatment of and/or prevention of cancer. This review discusses Camellia sinensis as well as the bioactive phytochemical compounds contained within. Clinical uses of tea are explored, and possible pathways for activity are discussed before examining the evidence for EGCG's potential for acting on these processes. EGCG is identified as being a possible lead phytochemical for future drug design investigations.
Keywords: Cancer; EGCG; Natural products; PI3K/Akt/mTOR; Prostate cancer.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Potential Therapeutic Targets of Epigallocatechin Gallate (EGCG), the Most Abundant Catechin in Green Tea, and Its Role in the Therapy of Various Types of Cancer.Molecules. 2020 Jul 9;25(14):3146. doi: 10.3390/molecules25143146. Molecules. 2020. PMID: 32660101 Free PMC article. Review.
-
Protective effects of a green tea polyphenol, epigallocatechin-3-gallate, against sevoflurane-induced neuronal apoptosis involve regulation of CREB/BDNF/TrkB and PI3K/Akt/mTOR signalling pathways in neonatal mice.Can J Physiol Pharmacol. 2017 Dec;95(12):1396-1405. doi: 10.1139/cjpp-2016-0333. Epub 2017 Jul 5. Can J Physiol Pharmacol. 2017. PMID: 28679060
-
Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.Biochem Pharmacol. 2011 Dec 15;82(12):1807-21. doi: 10.1016/j.bcp.2011.07.093. Epub 2011 Jul 30. Biochem Pharmacol. 2011. PMID: 21827739 Free PMC article. Review.
-
Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.Biochem Biophys Res Commun. 2011 Mar 11;406(2):194-9. doi: 10.1016/j.bbrc.2011.02.010. Epub 2011 Feb 15. Biochem Biophys Res Commun. 2011. PMID: 21300025
-
Modulation of phosphatidylinositol-3-kinase/protein kinase B- and mitogen-activated protein kinase-pathways by tea polyphenols in human prostate cancer cells.J Cell Biochem. 2004 Feb 1;91(2):232-42. doi: 10.1002/jcb.10737. J Cell Biochem. 2004. PMID: 14743383
Cited by
-
Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy.J Nanobiotechnology. 2024 Apr 18;22(1):192. doi: 10.1186/s12951-024-02458-9. J Nanobiotechnology. 2024. PMID: 38637848 Free PMC article.
-
Targeting Cancer Hallmarks with Epigallocatechin Gallate (EGCG): Mechanistic Basis and Therapeutic Targets.Molecules. 2024 Mar 20;29(6):1373. doi: 10.3390/molecules29061373. Molecules. 2024. PMID: 38543009 Free PMC article. Review.
-
Nano-Based Drug Delivery of Polyphenolic Compounds for Cancer Treatment: Progress, Opportunities, and Challenges.Pharmaceuticals (Basel). 2023 Jan 10;16(1):101. doi: 10.3390/ph16010101. Pharmaceuticals (Basel). 2023. PMID: 36678599 Free PMC article. Review.
-
Advances in Immunosuppressive Agents Based on Signal Pathway.Front Pharmacol. 2022 May 26;13:917162. doi: 10.3389/fphar.2022.917162. eCollection 2022. Front Pharmacol. 2022. PMID: 35694243 Free PMC article. Review.
-
The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review.Int J Mol Sci. 2022 May 28;23(11):6075. doi: 10.3390/ijms23116075. Int J Mol Sci. 2022. PMID: 35682754 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous